Coronary Heart Disease (CHD), which is caused by plaque buildup on the arterial wall, affects over 600,000 people annually. CHD is commonly treated by the insertion of a stent. These stents are typically comprised of stainless steel 316L (SS316L). Upon insertion, the stent can damage the endothelial membrane, promoting platelet aggregation. If not treated properly, the collection of platelets at the stent site can ultimately result the reduction of blood flow through coronary arteries. Nonsteroidal Anti-Inflammatory Drugs (NSAIDS) such as aspirin have been utilized to prevent platelet aggregation and subsequent clotting via inhibiting the enzyme cyclooxygenase (COX). Large systemic administrations of these drugs are necessary to achieve optimal platelet reduction, resulting in the risk of internal bleeding. The direct delivery of a lower dosage NSAID like aspirin to the site of the stent would reduce this risk along with other side effects. Aspirin was immobilized to the surface of SS316L via an aspirin acid chloride esterification, utilizing self-assembled monolayers (SAMs) as linkers to the surface. Diffuse reflectance infrared Fourier transform spectroscopy, matrix assisted laser desorption/ionization time of flight (MALDI-TOF) mass spectrometry, and contact angle were implemented to confirm the successful attachment of aspirin to the surface. Simulated body fluid testing as well as platelet assays will assess the stability of the immobilized drug and its ability to reduce platelet aggregation respectively.

Localized drug delivery of aspirin to stent sites via self-assembled monolayers

255th National Meeting (2018)

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.